Camerong: UK Prime Minister trips over 'Rescue Remedy' and Cancer Drugs Fund
This article was originally published in Scrip
Britain’s Prime Minister, David Cameron, came to yesterday's Financial Times Pharmaceutical and Biotechnology conference in London with what presumably was a triumphal announcement to the pharmaceutical industry about a raft of encouraging measures for the British life science industry (see accompanying story).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.